For Gilenya US launch, Novartis reveals pricing and co-pay plan
This article was originally published in Scrip
Executive Summary
The first oral treatment for multiple sclerosis, Novartis's Gilenya (fingolimod), became available to US patients in the first week of this month, and patient groups (such as MSWorld Forum and Wellsphere.com) and MS bloggers immediately expressed shock and dismay when they learned from press reports that the wholesale price would be around $4,000 a month, making it one of the most expensive drugs for the disease.